EUDR CN 38249961: chemical preparations
-- Intermediate products of the antibiotics manufacturing process obtained from the fermentation of Streptomyces tenebrarius, whether or not dried, for use in the manufacture of human medicaments of heading 3004
- EUDR scope
- From 30 Dec 2027
- Commodity
- oil palm
- Large and medium
- 30 Dec 2027
- Micro and small
- 30 Dec 2027
Due diligence for CN 38249961
Before you place CN 38249961 on the EU market or export it, you file a due diligence statement that the oil palm in it is deforestation-free and legally produced (Art. 4). You collect the geolocation of every plot it came from and the date of production (Art. 9). Annex I lists this line with ex, so it covers only the goods made from oil palm.
Delegated Regulation (EU) 2026/2102 added this line, and it applies from 30 Dec 2027 whatever the size of your company.
By country of production
| Country risk | Due diligence | Minimum checks |
|---|---|---|
| Low | Simplified, no risk assessment (Art. 13) | 1% |
| Standard | Full risk assessment and mitigation (Art. 10, 11) | 3% |
| High | Full risk assessment and mitigation (Art. 10, 11) | 9% |
Other EUDR codes under 3824
- Petroleum sulphonates, excluding petroleum sulphonates of alkali metals, of ammonium or of ethanolamines; thiophenated sulphonic acids of oils obtained from bituminous minerals, and their salts
- Ion-exchangers
- Getters for vacuum tubes
- Pyrolignites (for example, of calcium); crude calcium tartrate; crude calcium citrate
- Naphthenic acids, their water-insoluble salts and their esters
- - Anti-scaling and similar compounds
- - Preparations for electroplating
- - Mixtures of mono-, di- and tri-, fatty acid esters of glycerol (emulsifiers for fats)
- -- Intermediate products from the manufacture of monensin salts
- -- Other
- - Auxiliary products for foundries (other than those of subheading 38241000)
- - Fireproofing, waterproofing and similar protective preparations used in the building industry
- -- Lithium niobate wafer, undoped
- -- Mixture of amines derived from dimerised fatty acids, of an average molecular weight of 520 or more but not exceeding 550
- -- 3-(1-Ethyl-1-methylpropyl)isoxazol-5-ylamine, in the form of a solution in toluene
- -- Mixtures consisting mainly of dimethyl methylphosphonate, oxirane and diphosphorus pentaoxide
- --- In the form of a liquid at 20 °C
- --- Other
- -- Other
Deutsch-- Zwischenerzeugnisse der Antibiotikagewinnung, erhalten aus der Fermentation von Streptomyces tenebrarius, auch getrocknet, zum Herstellen von Arzneiwaren der Position 3004 für die Humanmedizin
Français-- Produits intermédiaires obtenus au cours de la fabrication d'antibiotiques, provenant de la fermentation de Streptomyces tenebrarius, même séchés, destinés à la fabrication de médicaments du no 3004 pour la médecine humaine
EUDR dataset 2026-09-18. Scope: Annex I to Regulation (EU) 2023/1115, as amended by
Regulation (EU) 2025/2650 and Delegated Regulation (EU) 2026/2102. Country risk: Implementing Regulation (EU)
2025/1093.